Two lives, one fight: navigating rectal cancer in pregnancy with multidisciplinary precision

Rectal cancer during pregnancy represents a clinical paradox in which the instinct to protect new life directly intersects with the urgency to preserve another. With an incidence of approximately 1 in 13,000 pregnancies, this rare condition challenges not only clinical decision-making but also the ethical and emotional dimensions of contemporary medical care. A 32-year-old primigravida at 26 weeks of gestation presented with rectal bleeding and was diagnosed with stage T4bN+M0 rectal adenocarcinoma. Despite the conventional recommendation of pregnancy termination in such circumstances, the patient expressed a strong desire to continue the pregnancy. A multidisciplinary team comprising colorectal surgeons, medical oncologists, radiation oncologists, and maternal-fetal medicine specialists developed a unified and coordinated treatment plan. The patient received neoadjuvant CAPOX (capecitabine [Xeloda] and oxaliplatin) chemotherapy during pregnancy, underwent cesarean delivery at 36 weeks of gestation, and subsequently completed postpartum chemoradiotherapy followed by curative laparoscopic oncologic resection. The child was delivered healthy, and the mother remained disease-free at a 5-year follow-up. This case demonstrates that life-threatening malignancy and ongoing pregnancy can coexist without compromise. Through carefully timed interventions, close cross-specialty collaboration, and respect for patient autonomy, both maternal and fetal outcomes were excellent. Within the evolving landscape of personalized cancer care, this case challenges outdated paradigms and reframes pregnancy not as a contraindication, but as a clinical variable that can be managed with precision and compassion. In addition to this illustrative case, we provide a focused review of the current literature to guide clinicians navigating this rare and complex clinical scenario.